The revolutionary role of CRISPR in cardiology: A new frontier in cardiovascular medicine.

Rodriguez Thomas*

Department of Nephrology and Hypertension, University of Minnesota, United States

Introduction

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, accounting for nearly 18 million deaths annually. Despite significant advancements in medical technology, conventional treatments such as medication, surgery, and lifestyle modifications often fall short in providing a definitive cure. The advent of gene-editing technology, particularly CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), has revolutionized the landscape of molecular medicine. Initially developed for bacterial immune defense, CRISPR has evolved into a powerful tool for precise genetic modifications, offering new hope in cardiology. This article explores the applications, potential benefits, ethical concerns, and future prospects of CRISPR in cardiovascular research and treatment.CRISPR technology enables scientists to edit DNA sequences with unprecedented accuracy. The system comprises two key components: the Cas9 enzyme, which acts as molecular scissors, and a guide RNA (gRNA) that directs Cas9 to the target DNA sequence. Once the specific sequence is identified, Cas9 introduces a cut, allowing for the addition, deletion, or alteration of genetic material. This groundbreaking technique has demonstrated immense potential in treating genetic disorders, including those associated with heart disease. [1,2].

Several cardiovascular diseases have a genetic basis, such as hypertrophic cardiomyopathy (HCM), familial hypercholesterolemia (FH), and Marfan syndrome. CRISPR offers the ability to correct mutations in genes responsible for these conditions. For example, researchers have successfully used CRISPR to correct mutations in the MYBPC3 gene, which causes HCM, thereby preventing disease progression in animal models. Atherosclerosis, characterized by the buildup of plaques in arterial walls, is a primary contributor to heart attacks and strokes. CRISPR can be utilized to target genes such as PCSK9, which regulates cholesterol levels. Studies have demonstrated that knocking out the PCSK9 gene in animal models leads to a significant reduction in low-density lipoprotein (LDL) cholesterol, thereby decreasing the risk of atherosclerosis and related complications. [3,4].

Myocardial infarction (heart attack) often results in irreversible damage to cardiac tissue. CRISPR-based strategies aim to stimulate the regeneration of cardiomyocytes (heart muscle cells) by reprogramming existing cells or activating specific genes involved in tissue repair. This approach holds promise in reducing the long-term effects of heart failure. Genetic mutations affecting ion channels can lead to life-threatening arrhythmias, such as long QT syndrome and Brugada syndrome. CRISPR has been explored as a means to repair these mutations, offering a potential permanent cure for patients prone to sudden cardiac arrest due to electrical conduction abnormalities. [5,6].

The integration of CRISPR with precision medicine allows for customized treatment approaches tailored to an individual's genetic makeup. By identifying and modifying patient-specific genetic risk factors, clinicians can provide targeted interventions, reducing the likelihood of adverse cardiac events. While CRISPR offers groundbreaking possibilities in cardiology, its clinical application raises several ethical and safety concerns. Despite its precision, CRISPR is not infallible, and unintended genetic modifications (off-target effects) may lead to unforeseen health issues, including cancer or other genetic disorders. [7,8].

Editing germline (heritable) DNA could impact future generations, raising ethical dilemmas regarding consent and long-term consequences. The potential for designer babies and genetic inequality further complicates this issue.The widespread adoption of CRISPR-based therapies in cardiology faces regulatory hurdles, as stringent approvals are required to ensure safety and efficacy. Additionally, the high cost of gene-editing treatments may limit accessibility for patients in low- and middle-income countries. [9,10].

Conclusion

CRISPR technology has ushered in a new era of precision medicine, offering unparalleled opportunities for treating and preventing cardiovascular diseases. Ongoing research and clinical trials continue to refine its applications, ensuring improved accuracy and reduced risks. As advancements in gene-editing techniques progress, CRISPR may soon become an integral component of mainstream cardiovascular treatment.

References

1. Delcroix M, Kerr K, Fedullo P. Chronic thromboembolic pulmonary hypertension. Epidemiology and risk factors. Ann Am Thorac Soc.2016;13(3):S201–S206.

***Correspondence to:** Rodriguez Thomas*, Department of Nephrology and Hypertension, University of Minnesota, United States. Email: Rodriguezt@um.edu

Received: *01-Jan-2025, Manuscript No. AACC-25-161491;* ***Editor assigned:*** *02-Jan-2025, Pre QC No. AACC-25-161491(PQ);* ***Reviewed:****15-Jan-2025, QC No. AACC-25-161491;* ***Revised:*** *20-Jan-2025, Manuscript No. AACC-25-161491(R),* ***Published:*** *27-Jan-2025,DOI:10.35841/aacc-9.1.364*

Citation: *Thomas R. The revolutionary role of CRISPR in cardiology: A new frontier in cardiovascular medicine. Curr Trend Cardiol. 2025;9(1):364*

2. Goldhaber SZ, Hennekens CH, Evans DA, et al. Factors associated with correct antemortem diagnosis of major pulmonary embolism.Am J Med.1982;73(6):822-826.

3. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women.JAMA.1997;277(8):642-645.

4. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use.Br J Haematol.1997;97(4):775-784.

5. Smith SB, Geske JB, Kathuria P, et al. Analysis of national trends in admissions for pulmonary embolism. Chest.2016;150(1):35-45.

6. Basso C, Valente M, Poletti A, et al. Surgical pathology of primary cardiac and pericardial tumors.Eur J Cardiothorac Surg.1997;12:730–737.

7. Jain D, Maleszewski JJ, Halushka MK. Benign cardiac tumors and tumor like conditions.Ann Diagn Pathol.2010;14:215–230.

8. Jain S, Maleszewski JJ, Stephenson CR, et al. Current diagnosis and management of cardiac myxomas.Expert Rev Cardiovasc Ther.2015;13:369–375.

9. Maleszewski JJ, Anavekar NS, Moynihan TJ, et al. Pathology, imaging, and treatment of cardiac tumours. Nat Rev Cardiol.2017;14(9):536–549.

10. Oliveira GH, Al-Kindi SG, Hoimes C, et al. Characteristics and survival of malignant cardiac tumors: a 40-year analysis of > 500 patients.Circulation.2015;132:2395–2402.

Citation: *Thomas R. The revolutionary role of CRISPR in cardiology: A new frontier in cardiovascular medicine. Curr Trend Cardiol. 2025;9(1):364*